Dyno Therapeutics news
Dyno empowers a diverse team of the best problem-solvers to drive cutting-edge science toward improving patient health. Our mission is to build the ideal capsid and solve the challenges of vivo gene delivery. We call ourselves AAViators and are engaged in Collective Innovation aswe aim to maximize our impact on patients through the development of groundbreaking technologies.
Dyno’s Data Science team hosted its first class of interns amidst the socially distant heat of summer 2020. Five outstanding individuals joined us to help tackle challenges in computational biology, machine learning, software engineering, and, of course, remote company building.
These individuals left lasting contributions to our science and our culture. This post is an opportunity to hear their stories.
Our 2020 class o
The capsid of Adeno-associated Virus (AAV) is a naturally occurring, replication-deficient, virus that is widely considered the frontrunner for solving the delivery problem in gene therapy. These viruses are known to be harmless to humans, and are relatively simple to manipulate. One well-known drawback of natural capsids however, which are currently used for delivery, is that many patients with pre-existing immunity to the virus (due to previous natural exposure) may be ineligible for
The human body consists of trillions of cells, each possessing their own copy of DNA that provides the blueprint for making a human. Despite sharing the same DNA, different cells activate a varied mix of genes within them to enable differentiation into various tissues and organs. For millions of people, unfortunately, some of these genes do not function properly, resulting in diseases and conditions that are sometimes severely debilitating.
Currently, there ar